DE10196213B4 - Verwendung von Tetrahydropiperin zur Erhöhung der Bioverfügbarkeit von Nährstoffen und pharmazeutischen Präparationen - Google Patents

Verwendung von Tetrahydropiperin zur Erhöhung der Bioverfügbarkeit von Nährstoffen und pharmazeutischen Präparationen Download PDF

Info

Publication number
DE10196213B4
DE10196213B4 DE10196213.4A DE10196213A DE10196213B4 DE 10196213 B4 DE10196213 B4 DE 10196213B4 DE 10196213 A DE10196213 A DE 10196213A DE 10196213 B4 DE10196213 B4 DE 10196213B4
Authority
DE
Germany
Prior art keywords
tetrahydropiperine
active ingredient
absorption
nutrient
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE10196213.4A
Other languages
German (de)
English (en)
Other versions
DE10196213T1 (de
Inventor
Muhammed Majeed
Vladimir Badmaev
Kumar Rajinder Bammi
Subbalakshmi Prakash
Sankaran Natarajan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sami Chemicals and Extracts Ltd
Sabinsa Corp
Original Assignee
Sami Chemicals and Extracts Ltd
Sabinsa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sami Chemicals and Extracts Ltd, Sabinsa Corp filed Critical Sami Chemicals and Extracts Ltd
Application granted granted Critical
Publication of DE10196213B4 publication Critical patent/DE10196213B4/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)
DE10196213.4A 2000-05-19 2001-05-21 Verwendung von Tetrahydropiperin zur Erhöhung der Bioverfügbarkeit von Nährstoffen und pharmazeutischen Präparationen Expired - Lifetime DE10196213B4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20524500P 2000-05-19 2000-05-19
US60/205,245 2000-05-19
US27797901P 2001-03-23 2001-03-23
US60/277,979 2001-03-23
PCT/US2001/016070 WO2001089571A2 (en) 2000-05-19 2001-05-21 Method of increased bioavailability of nutrients and pharmaceutical preparations with tetrahydropiperine and its analogues and derivatives

Publications (1)

Publication Number Publication Date
DE10196213B4 true DE10196213B4 (de) 2020-12-17

Family

ID=26900240

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10196213.4A Expired - Lifetime DE10196213B4 (de) 2000-05-19 2001-05-21 Verwendung von Tetrahydropiperin zur Erhöhung der Bioverfügbarkeit von Nährstoffen und pharmazeutischen Präparationen
DE10196213T Granted DE10196213T1 (de) 2000-05-19 2001-05-21 Verfahren erhöhter Bioverfügbarkeit von Nährstoffen und pharmazeutische Präparationen mit Tetrahydropiperin und Analoga und Derivaten davon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10196213T Granted DE10196213T1 (de) 2000-05-19 2001-05-21 Verfahren erhöhter Bioverfügbarkeit von Nährstoffen und pharmazeutische Präparationen mit Tetrahydropiperin und Analoga und Derivaten davon

Country Status (6)

Country Link
US (1) US6849645B2 (https=)
JP (1) JP4098985B2 (https=)
AU (1) AU2001278849A1 (https=)
DE (2) DE10196213B4 (https=)
GB (1) GB2380675B (https=)
WO (1) WO2001089571A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105576B2 (en) * 2002-04-24 2006-09-12 Research Development Foundation Synergistic effects of nuclear transcription factor NF-κB inhibitors and anti-neoplastic agents
WO2004000229A2 (en) * 2002-06-24 2003-12-31 Research Development Foundation Treatment of human multiple myeloma by curcumin
WO2004067018A1 (en) * 2003-01-30 2004-08-12 Council Of Scientific And Industrial Research Bioavailability enhancing activity of carum carvi extracts and fractions thereof
AU2004320907A1 (en) 2003-08-26 2006-04-13 Research Development Foundation Osteoclastogenesis inhibitors and uses thereof
WO2006121421A2 (en) * 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060130675A1 (en) * 2004-11-30 2006-06-22 Crawford David S Transdermal nutritional supplement delivery patch
WO2006127905A2 (en) 2005-05-24 2006-11-30 Chrono Therapeutics, Inc. Portable drug delivery device
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20080138417A1 (en) * 2006-11-22 2008-06-12 Charles Grigsby Topical Composition And Method Of Forming
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
US10105487B2 (en) 2013-01-24 2018-10-23 Chrono Therapeutics Inc. Optimized bio-synchronous bioactive agent delivery system
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US10898537B2 (en) 2015-07-31 2021-01-26 Delivra Inc. Transdermal formulations for delivery of capsaicinoids
KR102655937B1 (ko) * 2016-09-27 2024-04-11 (주)아모레퍼시픽 코스모페린을 포함하는 항스트레스 조성물
AU2017343886B2 (en) * 2016-10-14 2023-07-06 Cipla Limited Pharmaceutical compositions comprising rifaximin
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US20200268761A1 (en) * 2017-09-19 2020-08-27 Cipla Limited Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US20200179362A1 (en) * 2018-12-05 2020-06-11 James E. Beecham Dietary supplement comprising glucuronidation inhibition assist for healthful daily synergy of anti-inflammation, cellular anti-oxidant boost, cellular protein clean-up boost
JP7163261B2 (ja) * 2019-09-27 2022-10-31 富士フイルム株式会社 水中油型乳化組成物、及び皮膚外用剤
CN115670998A (zh) * 2022-11-18 2023-02-03 广州澳莱娜生物科技有限公司 一种祛痘控油亮肤组合物及其制备方法
CN115813822B (zh) * 2022-12-16 2024-06-25 厦门海尼新创生物科技有限公司 一种高效祛痘组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972382A (en) * 1995-02-24 1999-10-26 Sabinsa Corporation Use of piperine as a bioavailability enhancer
WO2000002544A2 (en) * 1998-07-13 2000-01-20 Btg International Limited Use of piperine for treating skin pigmentation disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT398259B (de) * 1982-09-30 1994-11-25 Dainippon Jochugiku Kk Thermischer räucherapparat für ein chemisches präparat
DE4392300T1 (de) * 1992-05-21 1995-12-07 Jeff J Staggs Therapeutische Gebräuche von beißenden Pflanzen und Ihre Verwandten Zusammensetzungen
CA2098889A1 (en) * 1992-07-06 1994-01-07 Takashi Chinuki Slow-releasing medicated resin moldings and process for producing the same
IN176897B (https=) * 1993-10-29 1996-09-28 Cadila Lab Ltd
US5439891A (en) * 1993-10-29 1995-08-08 Kapil; Randhir S. Process for preparation of pharmaceutical composition with enhanced activity for treatment of tuberculosis and leprosy
JP2946452B2 (ja) * 1994-11-04 1999-09-06 カディラ ラボラトリーズ リミテッド ピペリンを含む組成物
EP0935964A1 (en) * 1998-02-12 1999-08-18 Panacea Biotec Limited Pharmaceutical compositions containing NSAIDs and piperine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972382A (en) * 1995-02-24 1999-10-26 Sabinsa Corporation Use of piperine as a bioavailability enhancer
WO2000002544A2 (en) * 1998-07-13 2000-01-20 Btg International Limited Use of piperine for treating skin pigmentation disorders

Also Published As

Publication number Publication date
GB2380675A (en) 2003-04-16
WO2001089571A3 (en) 2002-03-07
US20020058695A1 (en) 2002-05-16
JP4098985B2 (ja) 2008-06-11
GB0229561D0 (en) 2003-01-22
US6849645B2 (en) 2005-02-01
AU2001278849A1 (en) 2001-12-03
JP2003534295A (ja) 2003-11-18
GB2380675B (en) 2004-11-03
DE10196213T1 (de) 2003-04-30
WO2001089571A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
DE10196213B4 (de) Verwendung von Tetrahydropiperin zur Erhöhung der Bioverfügbarkeit von Nährstoffen und pharmazeutischen Präparationen
EP1282446B1 (de) Pharmazeutische und/oder kosmetische zubereitung enthaltend ein organosiloxan und ein phospholipid
EP1267900B1 (de) Emulsion enthaltend einen triterpen-haltigen pflanzenextrakt, verfahren zur herstellung der emulsion sowie zur gewinnung des pflanzenextraktes
DE60118019T2 (de) Zusammensetzung enthaltend hydroxyzitronensäure und garcinol zur gewichtsreduzierung
DE69932248T2 (de) Entzündungshemmende ascorbinsäurederivate
EP1113795B1 (de) Tryptophanylester und deren n-acyl-derivate zur prävention und therapie von erkrankungen, die durch oxidationsprozesse verursacht oder verstärkt werden
DE3784695T2 (de) Gebrauch von Gramineenextrakten als Arzneimittel.
CH647534A5 (de) Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate.
DE60033383T2 (de) Verwendung von tetrahydrocurcuminoiden zur regulation von physiologischen und pathologischen fällen in der haut und mucosa
DE3511609C2 (https=)
DE10003620A1 (de) 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln
DE3603576A1 (de) Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
CA2994331A1 (en) Transdermal formulations for delivery of capsaicinoids
CH633182A5 (de) Heilmittel gegen hautlaesionen verschiedener genese.
Hashim et al. Antimicrobial ability and free-irritation effect of neem-based lotion cosmeceutical for skin care
EP1275382A2 (de) Hyperforin als Zytostatikum sowie Hyperforin-Salbe oder -Creme als Applikationsform
DE3633315C2 (https=)
DE2265399C2 (de) Antioxidativ und/oder tumorhemmend wirksames Mittel
EP3299026B1 (de) Extrakte aus samen von aframomum-arten und deren verwendung
EP0817623A1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
EP0450123A1 (de) Diclofenac-Natrium enthaltende pharmazeutische Zusammensetzung zur topischen Anwendung
EP2908836B1 (de) Pharmazeutische formulierung enthaltend curcumin
EP0845983A2 (de) Pharmazeutisches präparat mit trypanoziden eigenschaften
DE60216979T2 (de) Synergistische hepatoprotektive Zusammensetzung aus trans-Tetracos-15-ensäure und Apocynin und Verwendung davon
DE102013107024A1 (de) Methoden und Zusammensetzungen zum Behandeln, Modifizieren und Handhaben von Knochenkrebsschmerz